CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation

Background: RVU120 (SEL120), a novel CDK8/CDK19 kinase inhibitor, has shown high anti-tumor efficacy in AML cell lines and patient-derived cells (PDC). The first-in-human (FIH) Phase Ib dose escalation trial (CLI120-001) of RVU120 is currently ongoing in patients with relapsed/refractory (R/R) AML or High-Risk Myelodysplastic Syndromes (HR-MDS) at 5 sites in the US and 2 upcoming sites in Poland (NCT04021368). Here we present updated data from the first five cohorts up to 110 mg dose level.